SPRY

ARS Pharmaceuticals, Inc.

Fundamental data last updated:June 10, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/12/2026

Business Summary

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

 


Analyze SPRY on TradingView

VALUATION

P/E

-4.71

Market Cap ($M USD)

$933.45M

Forward P/E

8.91

PEG

0.06

PRICE TO SALES

9.43

PRICE TO BOOK

15.22

EV / EBITDA

-5.18

5-Year Average P/E

Free Cash Flow Yield

-18.78%

DCF Value

$-4.70

Graham Number

N/A

Price to FCF

-5.32

EV to FCF

-5.74

Earnings Yield

-21.21%

FCF Yield

-18.78%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.99

Next Year EPS Growth Estimate

$1.06

Next Year Revenue Growth Estimate

$68.06B

Return on Equity (ROE)

-153.61%

FREE CASH FLOW

Operating Margin

-204.49%

Debt-to-Equity

0.85

Piotroski F-Score

3

Altman Z-Score

-0.69

Return on Invested Capital (ROIC)

-85.06%

Current Ratio

4.94

Quick Ratio

4.77

Net Debt to EBITDA

-0.37

Interest Coverage

-82.92

Gross Profit margin

77.10%

FCF PER SHARE

$-1.77

REVENUE PER SHARE

$1.00

Analyze SPRY on TradingView

Gainseekers Quantitative Analysis

Summary

SPRY ARS Pharmaceuticals, Inc. presents a perplexing valuation scenario. Despite a Forward P/E of 4.94 suggesting potential growth, the market has priced it well below its DCF Value, indicating skepticism about future cash flows. The negative Earnings Yield and a dismal Altman Z-score of 0.58 highlight significant financial distress and risk of insolvency. The company’s negative ROIC and operating margin further underscore management’s struggle to generate returns. This stock appears mispriced, but not in a favorable way for risk-averse investors.

AI Exposure / Tech Reliance

In the biotechnology sector, SPRY is uniquely positioned to leverage AI for drug discovery and personalized medicine. The industry's rapid adoption of tech innovations could enhance its R&D efficiency. However, its current financial instability may hinder swift adaptation.

The Bull Case

For the bold investor, SPRY's potential lies in its explosive sales growth forecast of over 70 billion percent next year. This astronomical figure suggests untapped market opportunities or breakthrough products. Despite a low Piotroski F-Score, the high Current Ratio indicates robust liquidity, offering a cushion against short-term liabilities. The gross profit margin of 75.77% hints at strong pricing power, a critical asset for future profitability.

The Bear Case

The bear case for SPRY is glaringly evident in its structural weaknesses. A Price/Book ratio of 7.54 and Price/Sales of 10.30 reflect an overvalued stock relative to its tangible assets and revenue. The negative FCF Yield and Price to FCF ratio indicate poor cash flow generation, a red flag for sustainability. With a Return on Equity of -100.29%, the company is hemorrhaging value, making it a risky bet for any investor.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$25.50

Institutional Ownership %

1-Year Beta

0.80

Insider Buying % (6 Mo)

Distance to 52-Week High

101.06%

Distance to 52-Week Low

29.15%

EARNINGS SURPRISE %

-15.09%

50-DAY SMA

$8.20

200-DAY SMA

$9.73

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.